Star Equity (STRR) 10-Q 7 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 29, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	DIGIRAD CORP
Entity Central Index Key	707,388
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		19,356,070

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Diagnostic Services	$ 12,179	$ 11,340	$ 22,742	$ 20,895
Diagnostic Imaging	3,368	3,247	6,645	6,689
Total revenues	15,547	14,587	29,387	27,584
Cost of revenues:
Diagnostic Services	9,213	8,204	17,719	15,738
Diagnostic Imaging	1,567	1,878	3,253	3,899
Total cost of revenues	10,780	10,082	20,972	19,637
Gross profit	4,767	4,505	8,415	7,947
Operating expenses:
Marketing and sales	1,268	1,245	2,478	2,340
General and administrative	2,203	2,193	4,371	4,188
Amortization of intangible assets	133	104	238	170
Restructuring charges	0	138	0	579
Total operating expenses	3,604	3,680	7,087	7,277
Income from operations	1,163	825	1,328	670
Interest and other income, net
Interest and other income, net	11	15	22	32
Interest expense	(12)	(9)	(23)	(17)
Total other income (expense)	(1)	6	(1)	15
Income before income taxes	1,162	831	1,327	685
Income tax benefit (expense)	(65)	(8)	515	(10)
Net income	$ 1,097	$ 823	$ 1,842	$ 675
Net income (loss) per share - basic (in dollars per share)	$ 0.06	$ 0.04	$ 0.10	$ 0.04
Net income (loss) per share - diluted (in dollars per share	$ 0.06	$ 0.04	$ 0.09	$ 0.04
Weighted average shares outstanding – basic	19,263	18,554	19,036	18,536
Weighted average shares outstanding – diluted	19,726	18,839	19,511	18,831
Dividends declared per common share (in US$ per share)	$ 0.05	$ 0.05	$ 0.10	$ 0.10
Other comprehensive income:
Unrealized gain (loss) on marketable securities	$ (1)	$ 8	$ 13	$ (10)
Total other comprehensive income (loss)	(1)	8	13	(10)
Comprehensive income	$ 1,096	$ 831	$ 1,855	$ 665

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015		Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 14,886		$ 14,051
Securities available-for-sale	6,780		7,935
Accounts receivable, net	7,252		5,989
Inventories, net	4,016		3,644
Other current assets	668		856
Restricted cash	233		477
Total current assets	33,835		32,952
Property and equipment, net	6,034		4,766
Intangible assets, net	3,346		2,577
Goodwill	2,897	[1],[2]	1,337
Other assets	312		269
Total assets	46,424		41,901
Liabilities and stockholders’ equity
Accounts payable	2,752		1,423
Accrued compensation	2,343		3,261
Accrued warranty	166		176
Deferred revenue	1,613		1,644
Other accrued liabilities	2,429		1,789
Total current liabilities	9,303		8,293
Other liabilities	1,114		963
Total liabilities	$ 10,417		$ 9,256
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	$ 0		$ 0
Common stock, $0.0001 par value: 80,000,000 shares authorized; 19,356,070 and 18,615,945 shares issued and outstanding (net of treasury shares) at June 30, 2015 and December 31, 2014, respectively	2		2
Treasury stock, at cost; 2,588,484 shares at June 30, 2015 and December 31, 2014	(5,728)		(5,728)
Additional paid-in capital	155,276		153,769
Accumulated other comprehensive loss	(6)		(19)
Accumulated deficit	(113,537)		(115,379)
Total stockholders’ equity	36,007		32,645
Total liabilities and stockholders’ equity	$ 46,424		$ 41,901
[1]	As a result of our acquisition of MD Office on March 5, 2015, we recorded certain intangible assets (See Note 3).
[2]	mortization expense for intangible assets, net was $0.2 million and $0.2 million for the six months ended June 30, 2015 and 2014, respectively. Estimated amortization expense for intangible assets for the remainder of 2015 is $0.3 million, for 2016 is $0.5 million, for 2017 is $0.5 million, for 2018 is $0.5 million, for 2019 is $0.4 million, for 2020 is $0.4 million, and thereafter is $0.7 million.

Condensed Consolidated Balance4

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	19,356,070	18,615,945
Common stock, shares outstanding	19,356,070	18,615,945
Treasury stock, shares	2,588,484	2,588,484

Condensed Consolidated Stateme5

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net income	$ 1,842	$ 675
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	848	774
Amortization of intangible assets	238	170
Provision for bad debt	99	107
Stock-based compensation	285	111
Loss (gain) on sale of assets	10	(15)
Amortization of premiums on investments	68	105
Changes in operating assets and liabilities:
Accounts receivable	(950)	(640)
Inventories	(362)	444
Other assets	198	352
Accounts payable	1,180	634
Accrued compensation	(999)	(1,086)
Deferred revenue	(31)	(153)
Other liabilities	(424)	(15)
Restricted cash	244	(233)
Net cash provided by operating activities	2,246	1,230
Investing activities
Purchases of property and equipment	(879)	(770)
Net proceeds from sale of assets	17	27
Purchases of securities available-for-sale	0	(2,617)
Maturities of securities available-for-sale	1,100	350
Net cash received from (paid for) acquisition	3	(3,470)
Net cash provided by (used in) investing activities	241	(6,480)
Financing activities
Issuances of common stock	432	158
Dividends paid	(1,894)	(1,853)
Repayment of long-term debt	0	(131)
Repayment of obligations under capital leases	(190)	(89)
Net cash used in financing activities	(1,652)	(1,915)
Net increase (decrease) in cash and cash equivalents	835	(7,165)
Cash and cash equivalents at beginning of period	14,051	18,744
Cash and cash equivalents at end of period	14,886	11,579
Non-Cash Investing Activities
Assets acquired by entering into capital lease	724	217
Issuances of common stock for acquisition	$ 2,684	$ 0

The Company

The Company	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	The Company Digirad Corporation ("Digirad"), a Delaware corporation, is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services, and also provides cardiac event monitoring services. These services are provided to physician practices, hospitals, and imaging centers through our Diagnostic Services reportable segment. Digirad also sells solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products sold, through our Diagnostic Imaging reportable segment. These two reportable segments, Diagnostic Services and Diagnostic Imaging, are collectively referred to herein as the “Company.” The accompanying condensed consolidated financial statements include the operations of both segments. Intercompany accounts and transactions are accounted for at cost and have been eliminated in consolidation. All our long-lived assets are located in the United States and substantially all of our revenues arise from sales activity in the United States. Basis of Presentation The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (SEC) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (GAAP) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2014 , filed with the SEC on Form 10-K on March 6, 2015, include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows, and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. In addition, certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates. The financial results for the three and six months ended June 30, 2015 include the financial results of MD Office Solutions and Telerhythmics, LLC. See Note 3 to the unaudited condensed consolidated financial statements for more information related to the acquisition of MD Office Solutions and Telerhythmics, LLC. Recent Accounting Pronouncement In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers which supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. The guidance allows for either full retrospective or modified retrospective adoption and is currently scheduled to become effective for us in the first quarter of 2018. We are currently evaluating the alternative transition methods and the potential effects of the adoption of this guidance on our financial statements. We believe that no other new accounting guidance was adopted or issued during 2015 that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.

Basic and Diluted Net Income Pe

Basic and Diluted Net Income Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share, Basic and Diluted [Abstract]
Basic and Diluted Net Income Per Share	Basic and Diluted Net Income Per Share For the three and six months ended June 30, 2015 and 2014 , basic net income per common share is computed by dividing net income by the weighted average number of common shares and vested restricted stock units outstanding during the period. Diluted net income per common share is calculated to give effect to all dilutive securities, if applicable, using the treasury stock method. The following table sets forth the reconciliation of shares used to compute basic and diluted net income per share for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, (shares in thousands) 2015 2014 2015 2014 Weighted average shares outstanding - basic 19,263 18,554 19,036 18,536 Dilutive potential common stock outstanding: Stock options 445 285 459 295 Restricted stock units 18 — 16 — Weighted average shares outstanding - diluted 19,726 18,839 19,511 18,831 The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net income per share because their effect was anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (shares in thousands) 2015 2014 2015 2014 Stock options 2 102 2 83 Restricted stock units — — — — Total 2 102 2 83

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2015
Business Combinations [Abstract]
Acquisitions	On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC (Telerhythmics), a provider of 24 hour cardiac monitoring services. We paid to the sellers of the membership interest (the Sellers) aggregate up front consideration of $3.4 million and assumed approximately $131,000 in debt. In addition, there is an aggregate earn-out opportunity of up to $501,000 from the period March 14, 2014 through December 31, 2016 based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones. The Sellers will receive fifty percent (50%) of the EBITDA generated by the Telerhythmics business in excess of the EBITDA milestone amounts, which are as follows: • $415,000 of EBITDA for the period from the closing date through December 31, 2014, • $825,000 of EBITDA for the period from January 1, 2015 through December 31, 2015; and • $825,000 of EBITDA for the period from January 1, 2016 through December 31, 2016. At June 30, 2015 , we have estimated the fair value of the contingent earn-out opportunity to be $56,000 . The earn-out opportunity is estimated based on the expected performance of the business over the period from January 1, 2015 through December 31, 2016, utilizing an income approach. No earn-out consideration was earned by the Sellers for the period from the closing date through December 31, 2014. It is reasonably possible that our estimate of the earn-out potential could change in the near term. Any adjustment in the estimated earn-out opportunity until settled will be recorded as a gain or loss to current operations in the period the estimate changes. During the three months ended June 30, 2015 , the estimate of the fair value of the contingent consideration related to the Telerhythmics acquisition was reduced by $173,000 . The resulting gain was recognized as a reduction of general and administrative operating expense. The allocation of the purchase price to the assets acquired and liabilities assumed on the acquisition date was as follows: Allocation of purchase price Assets Current assets: Accounts receivable $ 256 Other current assets 34 Total current assets 290 Property and equipment 290 Intangible assets 2,580 Goodwill 1,153 Total assets $ 4,313 Accounts payable $ 36 Accrued compensation 169 Other accrued liabilities 356 Current portion of long-term debt 131 Total current liabilities 692 Other liabilities 174 Total liabilities $ 866 The long-term debt was subsequently paid in full on March 28, 2014. The goodwill recognized as part of the transaction primarily represents synergies between Digirad and Telerhythmics that were not separately identified as part of the acquisition valuation process. Telerhythmics activities are considered their own operating segment, which is aggregated into our Diagnostic Services reportable segment. The resulting goodwill from the acquisition is expected to be deductible for federal and state tax reporting purposes. The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2013. In deriving the proforma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2014 2013 2014 2013 Revenues $ 14,587 $ 14,455 $ 28,739 $ 27,414 Net income (loss) $ 836 $ (564 ) $ 862 $ (3,098 )

Inventories

Inventories	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis. (in thousands) June 30, December 31, Inventories: Raw materials $ 2,822 $ 2,439 Work-in-process 1,533 2,560 Finished goods 1,127 558 Total inventories 5,482 5,557 Less reserve for excess and obsolete inventories (1,466 ) (1,913 ) Total inventories, net $ 4,016 $ 3,644

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment (in thousands) June 30, December 31, Property and equipment: Machinery and equipment $ 24,897 $ 23,412 Computer hardware and software 3,309 2,917 Leasehold improvements 583 571 Total property and equipment 28,789 26,900 Less accumulated depreciation (22,755 ) (22,134 ) Total property and equipment, net $ 6,034 $ 4,766

Intangibles and Goodwill

Intangibles and Goodwill	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles and Goodwill	June 30, 2015 (in thousands) Weighted Average Useful Life (years) Gross Carrying Amount Accumulated Amortization Intangible Assets, Net (1) Intangible assets with indefinite useful lives: Goodwill (2) Indefinite $ 2,897 $ — $ 2,897 Intangible assets with finite useful lives: Customer relationships (2) 8.2 $ 5,489 $ (3,073 ) $ 2,416 Trademarks (2) 8.0 787 (98 ) 689 Patents 13.7 141 (121 ) 20 Covenants not to compete (2) 5.0 251 (30 ) 221 Total intangible assets, net $ 6,668 $ (3,322 ) $ 3,346 December 31, 2014 Weighted Average Useful Life (years) Gross Carrying Amount Accumulated Amortization Intangible Assets, Net (1) Intangible assets with infinite useful lives: Goodwill Indefinite $ 1,337 $ — $ 1,337 Intangible assets with finite useful lives: Customer relationships 8.6 $ 4,850 $ (2,904 ) $ 1,946 Trademarks 9.0 600 (53 ) 547 Patents 13.2 141 (116 ) 25 Covenants not to compete 5.0 70 (11 ) 59 Total intangible assets, net $ 5,661 $ (3,084 ) $ 2,577 (1) Amortization expense for intangible assets, net was $0.2 million and $0.2 million for the six months ended June 30, 2015 and 2014 , respectively. Estimated amortization expense for intangible assets for the remainder of 2015 is $0.3 million , for 2016 is $0.5 million , for 2017 is $0.5 million , for 2018 is $0.5 million , for 2019 is $0.4 million , for 2020 is $0.4 million , and thereafter is $0.7 million . (2) As a result of our acquisition of MD Office on March 5, 2015, we recorded certain intangible assets (See Note 3).

Restructuring Charges

Restructuring Charges	6 Months Ended
	Jun. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring Charges Facilities restructuring initiative On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the Facilities restructuring initiative). This action was undertaken as the facility had excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations. As a result of the Facilities restructuring initiative, we incurred a total of $0.7 million in restructuring charges which occurred solely during fiscal year 2014 . Facilities restructuring charges of $0.1 million and $0.6 million were incurred during the three and six months ended June 30, 2014 , respectively. No Facilities restructuring charges were incurred during the three or six months ended June 30, 2015 . The charges were comprised of lease termination, moving, and other related costs. All Facilities restructuring charges were included in the Diagnostic Imaging segment. Restructuring liabilities and associated charges were measured at fair value as incurred.

Financial Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Financial Instruments	Financial Instruments Assets and Liabilities Measured at Fair Value on a Recurring Basis. The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at June 30, 2015 and December 31, 2014 . Fair Value as of June 30, 2015 (in thousands) Level 1 Level 2 Level 3 Total Assets: Corporate debt securities $ — $ 6,780 $ — $ 6,780 Liabilities: Acquisition related contingent consideration $ — $ — $ 62 $ 62 Fair Value as of December 31, 2014 (in thousands) Level 1 Level 2 Level 3 Total Assets: Corporate debt securities $ — $ 7,935 $ — $ 7,935 Liabilities: Acquisition related contingent consideration $ — $ — $ 229 $ 229 The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, and/or offers. We did not reclassify any investments between levels in the fair value hierarchy during the six months ended June 30, 2015 . The acquisition related contingent consideration is related to our acquisition of Telerhythmics on March 13, 2014 and acquisition of MD Office on March 5, 2015 (See Note 3). We reassess the fair value of the contingent consideration to be settled in cash related to our acquisitions of Telerhythmics and MD Office on a quarterly basis using the income approach, which is a Level 3 measurement. During the six months ended June 30, 2015 , $6,000 of contingent consideration was established related to the MD Office acquisition, and the contingent consideration related to the Telerhythmics acquisition was reduced by $173,000 . The resulting gain related to the reduction of the Telerhythmics acquisition contingent consideration was recognized as a reduction of general and administrative operating expense. Significant assumptions used in the measurement include probabilities of achieving the EBITDA milestones and estimated future earnings. Securities Available for Sale Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income. The realized gains and losses on these sales were minimal for the three and six months ended June 30, 2015 and 2014 . The following table sets forth the composition of securities available-for-sale as of June 30, 2015 and December 31, 2014 . Maturity in Years Amortized Cost Unrealized Fair Value As of June 30, 2015 (in thousands) Gains Losses Corporate debt securities Less than 1 year $ 4,495 $ — $ (2 ) $ 4,493 Corporate debt securities 1-3 years 2,291 — (4 ) 2,287 $ 6,786 $ — $ (6 ) $ 6,780 Maturity in Years Amortized Cost Unrealized Fair Value As of December 31, 2014 (in thousands) Gains Losses Corporate debt securities Less than 1 year $ 4,650 $ — $ (5 ) $ 4,645 Corporate debt securities 1-3 years 3,304 — (14 ) 3,290 $ 7,954 $ — $ (19 ) $ 7,935

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Other matters. In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes During the six months ended June 30, 2015 , we recorded an income tax benefit of approximately $0.5 million related to the release of valuation allowance associated with the acquisition of MD Office. The valuation allowance release occurred when we recorded an increase to our deferred tax liability balance as a result of book and tax basis differences in acquired fixed, intangible and other assets of MD Office. As of December 31, 2014 , we had unrecognized tax benefits of approximately $1.6 million . Included in the unrecognized tax benefits were $1.3 million of tax benefits that, if recognized, would reduce our annual effective tax rate, subject to the valuation allowance. We do not expect our unrecognized tax benefits to change significantly over the next 12 months. We assess the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was our cumulative profitability over the three-year period ended June 30, 2015 . Such objective evidence limits the ability to consider other subjective evidence such as our projections for future income. On the basis of this evaluation, as of June 30, 2015 , a valuation allowance has been recorded as we cannot conclude that it is more likely than not that the existing deferred tax assets will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence such as our projected future income. Should our recent positive earnings trend continue into the future, it is reasonably possible that sufficient positive evidence will exist later in 2015 or 2016 to conclude that it is more likely than not that some or all of our existing deferred tax assets will be realized. We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2009; however, our net operating loss and research credit carry-forwards arising prior to that year are subject to adjustment. It is our policy to recognize interest expense and penalties related to income tax matters as a component of income tax expense.

Segments

Segments	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segments	Segments Our reporting segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2015 2014 2015 2014 Gross profit by segment: Diagnostic Services $ 2,966 $ 3,136 $ 5,023 $ 5,157 Diagnostic Imaging 1,801 1,369 3,392 2,790 Condensed consolidated gross profit $ 4,767 $ 4,505 $ 8,415 $ 7,947 Income (loss) from operations by segment: Diagnostic Services $ 407 $ 441 $ (130 ) $ 108 Diagnostic Imaging (1) 756 384 1,458 562 Condensed consolidated income from operations $ 1,163 $ 825 $ 1,328 $ 670 Depreciation and amortization: Diagnostic Services $ 526 $ 431 $ 943 $ 806 Diagnostic Imaging 72 60 143 138 Condensed consolidated depreciation and amortization $ 598 $ 491 $ 1,086 $ 944 (in thousands) June 30, 2015 December 31, 2014 Identifiable assets by segment: Diagnostic Services $ 22,260 $ 18,724 Diagnostic Imaging 24,164 23,177 Condensed Consolidated assets $ 46,424 $ 41,901 (1) Included in the Diagnostic Imaging income from operations for the three and six months ended June 30, 2014 , are approximately $0.1 million and $0.6 million of charges, respectively, associated with our Facilities restructuring initiative (See Note 7).

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	Subsequent Events Investment in Perma-Fix Medical, S.A. On July 27, 2015, we entered into a stock subscription agreement (the Agreement) with Perma-Fix Medical, S.A. (Perma-Fix Medical), a publicly traded company listed on the NewConnect market of the Warsaw Stock Exchange. Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services, Inc. (NASDAQ: PESI). Perma-Fix Medical is developing a proprietary process to produce Technetium-99m (Tc-99m) resin from non-enriched uranium sources for purposes of creating nuclear imaging isotopes. Under the terms of the Agreement, we invested $1 million USD in exchange for 71,429 ordinary shares of Perma-Fix Medical. In connection with the Investment, the Company's President and CEO was appointed to the Supervisory Board of Perma-Fix Medical. Upon Perma-Fix Medical successfully completing development of the new Tc-99m resin, Perma-Fix Medical will supply us or our preferred nuclear pharmacy supplier with Tc-99m at a preferred rate and we will purchase agreed upon quantities of such Tc-99m for our nuclear imaging operations either directly or in conjunction with our preferred nuclear pharmacy supplier. Dividend On August 7, 2015, the Company announced a cash dividend of $0.05 per share payable on August 31, 2015 to shareholders of record on August 21, 2015.

Financial Instruments (policies

Financial Instruments (policies)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments, Policy	The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, and/or offers.
Securities Available-for-sale, Policy	Securities Available for Sale Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income.

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share, Basic and Diluted [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the reconciliation of shares used to compute basic and diluted net income per share for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, (shares in thousands) 2015 2014 2015 2014 Weighted average shares outstanding - basic 19,263 18,554 19,036 18,536 Dilutive potential common stock outstanding: Stock options 445 285 459 295 Restricted stock units 18 — 16 — Weighted average shares outstanding - diluted 19,726 18,839 19,511 18,831
Schedule of Antidilutive Securities Excluded from Computation of Earnings (Loss) Per Share	The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net income per share because their effect was anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (shares in thousands) 2015 2014 2015 2014 Stock options 2 102 2 83 Restricted stock units — — — — Total 2 102 2 83

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2015
Business Acquisition [Line Items]
Schedule of Preliminary Allocation of Purchase Price	allocation of the purchase price to the assets acquired and liabilities assumed on the acquisition date was as follows: Allocation of purchase price Assets Current assets: Accounts receivable $ 256 Other current assets 34 Total current assets 290 Property and equipment 290 Intangible assets 2,580 Goodwill 1,153 Total assets $ 4,313 Accounts payable $ 36 Accrued compensation 169 Other accrued liabilities 356 Current portion of long-term debt 131 Total current liabilities 692 Other liabilities 174 Total liabilities $ 866
Schedule of Estimated Proforma Results	The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2013. In deriving the proforma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2014 2013 2014 2013 Revenues $ 14,587 $ 14,455 $ 28,739 $ 27,414 Net income (loss) $ 836 $ (564 ) $ 862 $ (3,098 )
MD Office [Member]
Business Acquisition [Line Items]
Schedule of Preliminary Allocation of Purchase Price	(in thousands) Allocation of purchase price Assets Current assets: Cash and cash equivalents $ 3 Accounts receivable 457 Other current assets 32 Total current assets 492 Property and equipment 481 Intangible assets 1,007 Goodwill 1,560 Other assets 26 Total assets $ 3,566 Liabilities Current liabilities: Accounts payable $ 149 Accrued compensation 81 Other accrued liabilities 87 Total current liabilities 317 Deferred tax liability 544 Other liabilities 6 Total liabilities $ 867
Consolidated Operating Results of Acquired Entity	Included within our consolidated operating results for the three and six months ended June 30, 2015 are MD Office operations for the period March 6, 2015 through June 30, 2015 as follows: (in thousands) Three Months Ended June 30, 2015 Six Months Ended Revenues $ 765 $ 981 Net income (loss) $ 41 $ (78 )
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	The following table summarizes the fair value of acquired identifiable intangible assets as of the acquisition date: (in thousands) Weighted Average Useful Lives (in years) Fair Value Customer relationships 7.0 $ 639 Trademarks 5.0 187 Covenants not to compete 5.0 181 Total intangible assets acquired, excluding goodwill 6.3 $ 1,007
Schedule of Estimated Proforma Results	The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2014. In deriving the proforma results, we utilized the historical operating results of MD Office and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2014. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2015 2014 2015 2014 Revenues $ 15,547 $ 15,395 $ 29,953 $ 29,146 Net income $ 1,150 $ 805 $ 2,045 $ 481

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis. (in thousands) June 30, December 31, Inventories: Raw materials $ 2,822 $ 2,439 Work-in-process 1,533 2,560 Finished goods 1,127 558 Total inventories 5,482 5,557 Less reserve for excess and obsolete inventories (1,466 ) (1,913 ) Total inventories, net $ 4,016 $ 3,644

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment (in thousands) June 30, December 31, Property and equipment: Machinery and equipment $ 24,897 $ 23,412 Computer hardware and software 3,309 2,917 Leasehold improvements 583 571 Total property and equipment 28,789 26,900 Less accumulated depreciation (22,755 ) (22,134 ) Total property and equipment, net $ 6,034 $ 4,766

Intangibles and Goodwill (Table

Intangibles and Goodwill (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	June 30, 2015 (in thousands) Weighted Average Useful Life (years) Gross Carrying Amount Accumulated Amortization Intangible Assets, Net (1) Intangible assets with indefinite useful lives: Goodwill (2) Indefinite $ 2,897 $ — $ 2,897 Intangible assets with finite useful lives: Customer relationships (2) 8.2 $ 5,489 $ (3,073 ) $ 2,416 Trademarks (2) 8.0 787 (98 ) 689 Patents 13.7 141 (121 ) 20 Covenants not to compete (2) 5.0 251 (30 ) 221 Total intangible assets, net $ 6,668 $ (3,322 ) $ 3,346 December 31, 2014 Weighted Average Useful Life (years) Gross Carrying Amount Accumulated Amortization Intangible Assets, Net (1) Intangible assets with infinite useful lives: Goodwill Indefinite $ 1,337 $ — $ 1,337 Intangible assets with finite useful lives: Customer relationships 8.6 $ 4,850 $ (2,904 ) $ 1,946 Trademarks 9.0 600 (53 ) 547 Patents 13.2 141 (116 ) 25 Covenants not to compete 5.0 70 (11 ) 59 Total intangible assets, net $ 5,661 $ (3,084 ) $ 2,577

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at June 30, 2015 and December 31, 2014 . Fair Value as of June 30, 2015 (in thousands) Level 1 Level 2 Level 3 Total Assets: Corporate debt securities $ — $ 6,780 $ — $ 6,780 Liabilities: Acquisition related contingent consideration $ — $ — $ 62 $ 62 Fair Value as of December 31, 2014 (in thousands) Level 1 Level 2 Level 3 Total Assets: Corporate debt securities $ — $ 7,935 $ — $ 7,935 Liabilities: Acquisition related contingent consideration $ — $ — $ 229 $ 229
Available-for-sale Securities	The following table sets forth the composition of securities available-for-sale as of June 30, 2015 and December 31, 2014 . Maturity in Years Amortized Cost Unrealized Fair Value As of June 30, 2015 (in thousands) Gains Losses Corporate debt securities Less than 1 year $ 4,495 $ — $ (2 ) $ 4,493 Corporate debt securities 1-3 years 2,291 — (4 ) 2,287 $ 6,786 $ — $ (6 ) $ 6,780 Maturity in Years Amortized Cost Unrealized Fair Value As of December 31, 2014 (in thousands) Gains Losses Corporate debt securities Less than 1 year $ 4,650 $ — $ (5 ) $ 4,645 Corporate debt securities 1-3 years 3,304 — (14 ) 3,290 $ 7,954 $ — $ (19 ) $ 7,935

Segments (Tables)

Segments (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Our reporting segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2015 2014 2015 2014 Gross profit by segment: Diagnostic Services $ 2,966 $ 3,136 $ 5,023 $ 5,157 Diagnostic Imaging 1,801 1,369 3,392 2,790 Condensed consolidated gross profit $ 4,767 $ 4,505 $ 8,415 $ 7,947 Income (loss) from operations by segment: Diagnostic Services $ 407 $ 441 $ (130 ) $ 108 Diagnostic Imaging (1) 756 384 1,458 562 Condensed consolidated income from operations $ 1,163 $ 825 $ 1,328 $ 670 Depreciation and amortization: Diagnostic Services $ 526 $ 431 $ 943 $ 806 Diagnostic Imaging 72 60 143 138 Condensed consolidated depreciation and amortization $ 598 $ 491 $ 1,086 $ 944
Reconciliation of Assets from Segment to Consolidated	(in thousands) June 30, 2015 December 31, 2014 Identifiable assets by segment: Diagnostic Services $ 22,260 $ 18,724 Diagnostic Imaging 24,164 23,177 Condensed Consolidated assets $ 46,424 $ 41,901 (1) Included in the Diagnostic Imaging income from operations for the three and six months ended June 30, 2014 , are approximately $0.1 million and $0.6 million of charges, respectively, associated with our Facilities restructuring initiative (See Note 7).

The Company (Details)

The Company (Details)	6 Months Ended
	Jun. 30, 2015segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	2

Basic and Diluted Net Income 27

Basic and Diluted Net Income Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share, Basic and Diluted [Abstract]
Weighted average shares outstanding – basic	19,263	18,554	19,036	18,536
Dilutive potential common stock outstanding:
Stock options	445	285	459	295
Restricted stock units	18	0	16	0
Weighted average shares outstanding – diluted	19,726	18,839	19,511	18,831
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share	2	102	2	83
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share	2	102	2	83
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share	0	0	0	0

Acquisitions (Details)

Acquisitions (Details) - USD ($) shares in Thousands	Mar. 05, 2015	Mar. 13, 2014	Jun. 30, 2015		Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2015		Jun. 30, 2015		Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2014
Business Acquisition, Contingent Consideration [Line Items]
Issuances of common stock for acquisition									$ 2,684,000		$ 0
Net loss			$ 1,097,000		$ 823,000				1,842,000		675,000
Finite-Lived Intangible Assets, Net			3,346,000	[1]			$ 3,346,000	[1]	3,346,000	[1]			$ 2,577,000
MD Office [Member]
Business Acquisition, Contingent Consideration [Line Items]
Stock Issued During Period, Shares, Acquisitions	610
Issuances of common stock for acquisition	$ 2,684,000
business combination, settlement of accounts receivable owed to the Company	15,000
Aggregate earn-out opportunity	$ 400,000
Estimated fair value of contingent earn-out opportunity			6,000				6,000		6,000
Percentage of EBITDA to be received by sellers (percent)	50.00%
Transaction costs included within results for Telerhythmics			188,000				188,000		188,000
Cash and cash equivalents	$ 3,000
Accounts receivable	457,000
Other current assets	32,000
Total current assets	492,000
Property and equipment	481,000
Intangible assets	1,007,000
Goodwill	1,560,000
Other assets	26,000
Total assets	3,566,000
Accounts payable	149,000
Accrued compensation	81,000
Other accrued liabilities	87,000
Total current liabilities	317,000
Deferred tax liability	544,000
Other liabilities	6,000
Total liabilities	867,000
Revenues			15,547,000		15,395,000				29,953,000		29,146,000
Net income (loss)			1,150,000		805,000				$ 2,045,000		481,000
Revenues			765,000				981,000
Net loss			41,000				(78,000)
Finite-Lived Intangible Asset, Useful Life									6 years 3 months 12 days
Finite-Lived Intangible Assets, Net			1,007,000				1,007,000		$ 1,007,000
Telerhythmics [Member]
Business Acquisition, Contingent Consideration [Line Items]
Aggregate earn-out opportunity		$ 501,000
Estimated fair value of contingent earn-out opportunity			56,000				56,000		$ 56,000
Percentage of EBITDA to be received by sellers (percent)		50.00%
Membership interest acquired in business acquisition (percent)		100.00%
Aggregate upfront consideration paid		$ 3,400,000
Debt assumed in business acquisition		131,000
Reduction in estimate of fair value of the contingent consideration related to acquisition			173,000
Accounts receivable		256,000
Other current assets		34,000
Total current assets		290,000
Property and equipment		290,000
Intangible assets		2,580,000
Goodwill		1,153,000
Total assets		4,313,000
Accounts payable		36,000
Accrued compensation		169,000
Other accrued liabilities		356,000
Total current liabilities		692,000
Other liabilities		174,000
Total liabilities		866,000
Revenues					14,587,000	$ 14,455,000					28,739,000	$ 27,414,000
Net income (loss)					$ 836,000	$ (564,000)					$ 862,000	$ (3,098,000)
Year one to Year three [Member] | MD Office [Member]
Business Acquisition, Contingent Consideration [Line Items]
Aggregate earn-out opportunity	$ 650,000
Year one [Member] | Telerhythmics [Member]
Business Acquisition, Contingent Consideration [Line Items]
Aggregate earn-out opportunity		415,000
Year two [Member] | Telerhythmics [Member]
Business Acquisition, Contingent Consideration [Line Items]
Aggregate earn-out opportunity		825,000
Year three [Member] | Telerhythmics [Member]
Business Acquisition, Contingent Consideration [Line Items]
Aggregate earn-out opportunity		$ 825,000
Customer Relationships [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life									8 years 2 months 12 days	[2]			8 years 7 months 6 days
Finite-Lived Intangible Assets, Net			2,416,000	[1],[2]			2,416,000	[1],[2]	$ 2,416,000	[1],[2]			$ 1,946,000
Customer Relationships [Member] | MD Office [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life									7 years
Finite-Lived Intangible Assets, Net			639,000				639,000		$ 639,000
Trademarks [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life									8 years	[2]			9 years
Finite-Lived Intangible Assets, Net			689,000	[1],[2]			689,000	[1],[2]	$ 689,000	[1],[2]			$ 547,000
Trademarks [Member] | MD Office [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life									5 years
Finite-Lived Intangible Assets, Net			187,000				187,000		$ 187,000
Covenants not to compete [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life									5 years	[2]			5 years
Finite-Lived Intangible Assets, Net			221,000	[1],[2]			221,000	[1],[2]	$ 221,000	[1],[2]			$ 59,000
Covenants not to compete [Member] | MD Office [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life									5 years
Finite-Lived Intangible Assets, Net			$ 181,000				$ 181,000		$ 181,000
[1]	mortization expense for intangible assets, net was $0.2 million and $0.2 million for the six months ended June 30, 2015 and 2014, respectively. Estimated amortization expense for intangible assets for the remainder of 2015 is $0.3 million, for 2016 is $0.5 million, for 2017 is $0.5 million, for 2018 is $0.5 million, for 2019 is $0.4 million, for 2020 is $0.4 million, and thereafter is $0.7 million.
[2]	As a result of our acquisition of MD Office on March 5, 2015, we recorded certain intangible assets (See Note 3).

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 2,822	$ 2,439
Work-in-process	1,533	2,560
Finished goods	1,127	558
Total inventories	5,482	5,557
Less reserve for excess and obsolete inventories	(1,466)	(1,913)
Total inventories, net	$ 4,016	$ 3,644

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	$ 28,789	$ 26,900
Less accumulated depreciation	(22,755)	(22,134)
Total property and equipment, net	6,034	4,766
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	24,897	23,412
Computer hardware and software [Member]
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	3,309	2,917
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	$ 583	$ 571

Intangibles and Goodwill (Detai

Intangibles and Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended			12 Months Ended
	Jun. 30, 2015		Jun. 30, 2014	Jun. 30, 2015		Jun. 30, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Goodwill, Gross	$ 2,897	[1]		$ 2,897	[1]		$ 1,337
Goodwill	2,897	[1],[2]		2,897	[1],[2]		1,337
Finite-Lived Intangible Assets, Gross	6,668			6,668			5,661
Finite-Lived Intangible Assets, Accumulated Amortization	(3,322)			(3,322)			(3,084)
Finite-Lived Intangible Assets, Net	3,346	[2]		3,346	[2]		$ 2,577
Amortization of intangible assets	133		$ 104	238		$ 170
Finite-Lived Intangible Assets, Amortization Expense, Remainder of 2015	300			300
Finite-Lived Intangible Assets, Amortization Expense, 2016	500			500
Finite-Lived Intangible Assets, Amortization Expense, 2017	500			500
Finite-Lived Intangible Assets, Amortization Expense, 2018	500			500
Finite-Lived Intangible Assets, Amortization Expense, 2019	400			400
Finite-Lived Intangible Assets, Amortization Expense, 2020	400			400
Finite-Lived Intangible Assets, Amortization Expense, thereafter	700			$ 700
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life				8 years 2 months 12 days	[1]		8 years 7 months 6 days
Finite-Lived Intangible Assets, Gross	5,489	[1]		$ 5,489	[1]		$ 4,850
Finite-Lived Intangible Assets, Accumulated Amortization	(3,073)	[1]		(3,073)	[1]		(2,904)
Finite-Lived Intangible Assets, Net	2,416	[1],[2]		$ 2,416	[1],[2]		$ 1,946
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life				8 years	[1]		9 years
Finite-Lived Intangible Assets, Gross	787	[1]		$ 787	[1]		$ 600
Finite-Lived Intangible Assets, Accumulated Amortization	(98)	[1]		(98)	[1]		(53)
Finite-Lived Intangible Assets, Net	689	[1],[2]		$ 689	[1],[2]		$ 547
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life				13 years 8 months 12 days			13 years 2 months 12 days
Finite-Lived Intangible Assets, Gross	141			$ 141			$ 141
Finite-Lived Intangible Assets, Accumulated Amortization	(121)			(121)			(116)
Finite-Lived Intangible Assets, Net	20	[2]		$ 20	[2]		$ 25
Covenants not to compete [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life				5 years	[1]		5 years
Finite-Lived Intangible Assets, Gross	251	[1]		$ 251	[1]		$ 70
Finite-Lived Intangible Assets, Accumulated Amortization	(30)	[1]		(30)	[1]		(11)
Finite-Lived Intangible Assets, Net	$ 221	[1],[2]		$ 221	[1],[2]		$ 59
[1]	As a result of our acquisition of MD Office on March 5, 2015, we recorded certain intangible assets (See Note 3).
[2]	mortization expense for intangible assets, net was $0.2 million and $0.2 million for the six months ended June 30, 2015 and 2014, respectively. Estimated amortization expense for intangible assets for the remainder of 2015 is $0.3 million, for 2016 is $0.5 million, for 2017 is $0.5 million, for 2018 is $0.5 million, for 2019 is $0.4 million, for 2020 is $0.4 million, and thereafter is $0.7 million.

Restructuring Charges - Facilit

Restructuring Charges - Facilities Restructuring Initiative (Details) - Facilities Restructuring Initiative [Member] $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2014USD ($)	Jan. 27, 2014ft²	Jan. 23, 2014ft²
Restructuring Cost and Reserve [Line Items]
Area of Real Estate Property | ft²				47,000	21,300
Restructuring and Related Cost, Incurred Cost	$ 0.1	$ 0.6	$ 0.7

Financial Instruments Assets an

Financial Instruments Assets and Liabilities at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	$ 6,786	$ 7,954
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(6)	(19)
Available-for-sale Securities	6,780	7,935
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure	0	0
Level 1 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	0	0
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure	0	0
Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	6,780	7,935
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure	62	229
Level 3 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	0	0
Total [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure	62	229
Total [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	6,780	7,935
Less than 1 year [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	4,495	4,650
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(2)	(5)
Available-for-sale Securities	4,493	4,645
1-3 years [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	2,291	3,304
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(4)	(14)
Available-for-sale Securities	$ 2,287	$ 3,290

Financial Instruments Securitie

Financial Instruments Securities Available for Sale (Details) - Jun. 30, 2015 - USD ($) $ in Thousands	Total
MD Office [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated fair value of contingent earn-out opportunity	$ 6
Telerhythmics [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated fair value of contingent earn-out opportunity	56
Reduction in estimate of fair value of the contingent consideration related to acquisition	$ 173

Income Tax (Details)

Income Tax (Details) - USD ($) $ in Thousands	Mar. 05, 2015	Dec. 31, 2014
Business Combination, Separately Recognized Transactions [Line Items]
Unrecognized tax benefits		$ 1,600
Unrecognized tax benefits that would impact effective tax rate		$ 1,300
MD Office [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Income tax benefit recorded	$ 544

Segments (Details)

Segments (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Gross profit by segment		$ 4,767	$ 4,505	$ 8,415	$ 7,947
Income (loss) from operations by segment		1,163	825	1,328	670
Depreciation and amortization		598	491	1,086	944
Diagnostic Imaging [Member]
Segment Reporting Information [Line Items]
Gross profit by segment		1,801	1,369	3,392	2,790
Income (loss) from operations by segment	[1]	756	384	1,458	562
Depreciation and amortization		72	60	143	138
Diagnostic Services [Member]
Segment Reporting Information [Line Items]
Gross profit by segment		2,966	3,136	5,023	5,157
Income (loss) from operations by segment		407	441	(130)	108
Depreciation and amortization		$ 526	$ 431	$ 943	$ 806
[1]	Included in the Diagnostic Imaging income from operations for the three and six months ended June 30, 2014, are approximately $0.1 million and $0.6 million of charges, respectively, associated with our Facilities restructuring initiative (See Note 7).

Segments Asset by Segment Detai

Segments Asset by Segment Detail (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Identifiable assets by segment	$ 46,424		$ 46,424		$ 41,901
Restructuring charges	0	$ 138	0	$ 579
Diagnostic Services [Member]
Segment Reporting Information [Line Items]
Identifiable assets by segment	22,260		22,260		18,724
Diagnostic Imaging [Member]
Segment Reporting Information [Line Items]
Identifiable assets by segment	$ 24,164		$ 24,164		$ 23,177

Subsequent Event Detail (Detail

Subsequent Event Detail (Details) - USD ($) $ / shares in Units, $ in Millions	Aug. 07, 2015	Jul. 27, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Subsequent Event [Line Items]
Dividends declared per common share (in US$ per share)			$ 0.05	$ 0.05	$ 0.10	$ 0.10
Subsequent Event [Member]
Subsequent Event [Line Items]
Dividends declared per common share (in US$ per share)	$ 0.05
Perma-Fix Medical S.A. [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Amount invested		$ 1
Shares received in exchange for investment made		71,429